ImmunityBio在2026年美国泌尿外科学会年会上,公布了其Nai联合BCG疗法,相较于Nadofaragene与TAR-200疗法,在完全缓解率方面展现出的积极疗效比较数据。
ImmunityBio在2026年美国泌尿外科学会年会上,公布了其Nai联合BCG疗法,相较于Nadofaragene与TAR-200疗法,在完全缓解率方面展现出的积极疗效比较数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.